• Bio-Techne introduces a streamlined brand architecture that organizes its technologies into three focused portfolio brands:
  
  R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™.
• The new brand structure reflects the scientific journey, connecting early discoveries to translational insight to clinical decision-making.
• The portfolio brands will debut at the AACR Annual Meeting 2026 and AAI's IMMUNOLOGY 2026™.

MINNEAPOLIS, April 16, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science research tools, analytical instruments, and diagnostics, today announced a streamlined brand architecture designed to enable scientists and clinicians to more easily find the answers they need based on their application and stage of research.

The company has organized its products and technologies under three focused portfolio brands — R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™ — aligning its solutions with the way modern science progresses from early discovery through translational insights to clinical diagnostics.

For 50 years, Bio-Techne has driven scientific discovery and clinical innovation through a diversified portfolio of industry-leading solutions—from high-quality proteins, antibodies, and small molecules to advanced technologies, including protein analytical instruments and spatial biology platforms, that enable breakthrough research.

"At Bio-Techne, our focus is empowering scientists and clinicians to achieve better answers that lead to more breakthroughs," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "By aligning our portfolio with the fast-paced progression of scientific research, we make it easier for customers to access the solutions they need to advance their work and accelerate scientific progress.

Kelderman adds, "Our updated brand structure strengthens our position as a trusted scientific partner, bringing greater alignment across our expanding portfolio and reinforcing our mission to improve the quality of life by catalyzing advances in science and medicine."

R&D Systems: Empowering Better Answers in Scientific Discovery

The R&D Systems¹ portfolio brings together Bio-Techne's trusted proteins, antibodies, immunoassays, small molecules and innovative instruments used by scientists worldwide. R&D Systems solutions help researchers generate reproducible results, validate discoveries, and advance early-stage research towards clinical application with confidence. As the starting point of the scientific journey, R&D Systems provides dependable tools needed to explore, experiment, and uncover new biological insights. R&D Systems also provides key GMP-grade reagents and tools essential for advancing cell and gene therapy workflows.

Bio-Techne Spatial: Empowering Better Answers in Translational Research

The Bio-Techne Spatial¹ portfolio leverages technologies that help researchers and clinicians translate biology and disease context across both the gold-standard RNAscope™ in situ hybridization technology and the automated COMET™ spatial hyperplex platform. Bio-Techne Spatial solutions enable scalable, high-resolution visualization of RNA and protein with multiomic analysis, delivering exceptional sensitivity and precision to reveal differences in cell structure, identify clinically relevant biomarkers, inform pathology-driven research questions and accelerate therapeutic discovery.

Bio-Techne Diagnostics: Empowering Better Answers in Diagnostics

The Bio-Techne Diagnostics¹ portfolio provides clinical laboratories and IVD manufacturers with assay kits, IVD‑grade reagents, antibodies, molecular controls, calibrators, and proficiency‑testing materials needed to design, develop, and validate reliable diagnostic assays. The portfolio supports the full lifecycle of assay development from early design through deployment at scale. By delivering high-quality raw materials and comprehensive assay solutions, Bio-Techne Diagnostics helps ensure accuracy, strengthens clinical decision‑making, and ultimately contributes to improved patient outcomes.

Together, these three portfolios create a clearer, more connected path for customers by providing a streamlined, end‑to‑end view of Bio‑Techne's solutions, aligning tools and technologies from discovery through translation to clinical diagnostics and accelerating scientific and clinical progress.

Bio-Techne will highlight its newly aligned portfolio at several upcoming scientific meetings, including the American Association for Cancer Research (AACR) Annual Meeting in San Diego and IMMUNOLOGY2026™ in Boston, USA.

Visit R&D Systems and Bio-Techne Spatial at AACR

Visit R&D Systems and Bio-Techne Spatial at AAI

ABOUT BIO-TECHNE

Bio‑Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high‑quality reagents, analytical instruments, and precision diagnostics.

Its portfolio is organized into three customer‑focused brands: R&D Systems™, Bio‑Techne Spatial™, and Bio‑Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision‑making.

Bio‑Techne operates in 34 locations worldwide and employs approximately 3,100 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.

For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the Company on social media at LinkedIn, X, or YouTube.

^{1 R&D Systems™ now includes the legacy brands Novus Biologicals™, Tocris Bioscience™, and ProteinSimple™; Bio-Techne Spatial now includes the legacy brands Lunaphore™, and Advanced Cell Diagnostics™; Bio-Techne Diagnostics now includes Asuragen®, Bionostics, Cliniqa, RNA Medical®, and R&D Systems™ Clinical Controls.}

MEDIA CONTACTS

Corporate Communications

media.relations@bio-techne.com

David Clair, Vice President Investor Relations

ir@bio-techne.com

Logo - https://mma.prnewswire.com/media/2470019/5919136/Bio_Techne_Corporation__logo_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/bio-techne-introduces-streamlined-brand-architecture-to-help-customers-navigate-solutions-faster-and-with-greater-clarity-302744701.html

Im hessischen Wirtschaftsministerium steht ein personeller Einschnitt an: Ressortchef Kaweh Mansoori (SPD) hat Ministerpräsident Boris Rhein (CDU) darum gebeten, seinen Staatssekretär Umut Sönmez mit sofortiger Wirkung aus dem Beamtenverhältnis zu entlassen. Das teilte das Ministerium am Montag mit. Offiziell nannte eine Sprecherin keine Gründe für den Schritt, sprach aber von einer Entscheidung, die rasch umgesetzt werden solle. Nach Angaben der Staatskanzlei ist für die formale Entlassung noch ein Kabinettsbeschluss erforderlich.

Hintergrund der Personalentscheidung sind Vorwürfe sexueller Belästigung gegen den 43-jährigen SPD-Politiker. Einem früheren Bericht des Hessischen Rundfunks zufolge läuft im Wirtschaftsministerium eine interne Untersuchung zu Vorkommnissen bei einer Fastnachtsfeier für Beschäftigte des Hauses. Bei der Veranstaltung soll es demnach zu einer sexuellen Belästigung gekommen sein. Sönmez soll laut dem Bericht eine Mitarbeiterin wiederholt angefasst, sie zum Tanzen gedrängt und unangemessen eng mit ihr getanzt haben. Die Betroffene habe sich anschließend offiziell im Ministerium beschwert.

Aus der Staatskanzlei hieß es, das für eine „gedeihliche Zusammenarbeit erforderliche Vertrauensverhältnis“ sei nicht mehr gegeben. Ministerpräsident Rhein werde Sönmez daher mit sofortiger Wirkung entlassen, sobald das Kabinett den formalen Beschluss gefasst habe. Politisch ist der Fall brisant, weil Sönmez als Amtschef bislang auch für Personalfragen im Haus zuständig war – ein Punkt, den die Grünen im Landtag bereits kritisch als möglichen Interessenkonflikt bei der Aufklärung der Vorwürfe bezeichnet hatten.

Sönmez selbst weist die gegen ihn erhobenen Anschuldigungen zurück. In einer von einem privaten Mail-Konto verschickten Stellungnahme sprach er von „vorverurteilender Presseberichterstattung“ über ein „angebliches Vergehen“ seinerseits. Zugleich begrüßte er seine Entlassung ausdrücklich, um Schaden vom Land Hessen, dem Ministerium, der Koalition und der SPD abzuwenden. Den Vorwurf einer sexuellen Belästigung weise er entschieden zurück, betonte Sönmez. Er begrüße die eingeleitete interne Untersuchung und erhoffe sich von dem im öffentlichen Dienst etablierten Verfahren die Möglichkeit zur Richtigstellung und Rehabilitation.